SHL is primed to exhibit at the Prefilled Syringe Seminar 2019 Tokyo from May 21-22. Visitors are welcomed to stop by SHL's stand to learn more about its innovations and industry-leading offerings.
As a long-standing exhibitor at this annual exhibition, which is hosted by the Parenteral Drug Association (PDA) Japan Chapter, SHL is set on presenting its strong pipeline of auto-injectors designed for high volume and high viscosity drug formulations. Top displays include the Bertha® auto-injector, developed to deliver highly viscous drugs in syringe volumes up to 2.25mL, and the Maggie® auto-injector, which is built with Needle Isolation Technology (NIT®) – an innovative solution that facilitates a cartridge-based architect while preventing sharps injuries.
SHL's Molly® family, including Molly® 1mL, Molly® 2.25mL and Molly® C, showcases SHL's self-developed, preconfigured technology for faster development timelines.
The rise of protein drugs and biologics in recent years have called for higher demands in SHL's drug delivery offerings. Executive Director of Business Development Mike Weng commented, "As a leading device manufacturer in the industry for 30 years, SHL is committed to innovation and research that advances our offerings in becoming biologics' best partner. This year, other than catching up on some industry talks with familiar faces, we are looking forward to expanding ties with potential partners."
Visit SHL at the Sola City Conference Center from May 21-22, where our experts will be on site to connect with visitors.
瑞健目前全球已有超過 4,000 名員工，主要分為以下事業群：
SHL Medical 主要為製藥和生技企業設計、研發、及製造高科技藥物傳輸系統，也提供終端組裝、醫材標籤及包裝相關服務
SHL Healthcare 從事居家及醫院護理器材之研發製造
SHL Technologies 提供醫療科技及工業設備之 OEM 製造與相關服務